Last updated: February 22, 2026
What Is NDC 51672-4146?
NDC 51672-4146 refers to a specific drug product listed in the U.S. National Drug Code (NDC) database. It corresponds to Venclexta (venetoclax) Tablets, indicated primarily for the treatment of chronic lymphocytic leukemia (CLL) and other hematologic malignancies.
Market Size and Sales Performance
Venclexta, developed by AbbVie, has become a significant player in the targeted cancer therapy space. Its rapid adoption is driven by favorable clinical trial data, label expansion, and competitive positioning against other hematologic cancer drugs.
Sales Data (2022–2023)
- 2022 U.S. sales: Approx. $2.8 billion.
- 2023 projected sales: Approx. $3.2 billion.
- Growth rate: 14% year-over-year (YoY).
Sales growth is driven by an expanding indication slate, increased adoption in first-line therapy, and ongoing clinical trials supporting additional uses.
Market Share and Competitive Landscape
Major competitors include:
- AbbVie's Venclexta (venetoclax) as a first-line BCL-2 inhibitor.
- Celgene's (now BMS) Imbruvica (ibrutinib).
- Gilead's Trodelvy (sacituzumab govitecan).
Venclexta holds approximately 45% of the oral targeted hematologic malignancy market share in the U.S., surpassing some competitors due to its efficacy profile and favorable tolerability.
Price Points and Cost Analysis
Current Wholesale Acquisition Cost (WAC)
- Per tablet: Around $320.
- Average daily dose: 400 mg (e.g., four 100 mg tablets).
- Monthly cost: Approximately $3,840.
Cost Drivers
- High-dose regimens for certain patients.
- Pack sizes and dosing schedules impact unit costs.
- Insurance coverage varies, with co-pay assistance programs reducing patient out-of-pocket expenses.
Pricing Comparison to Competitors
| Drug |
Average Monthly Price |
Indications |
Market Share (2023) |
| Venclexta (nalbetoclax) |
$3,840 |
CLL, AML |
45% |
| Imbruvica |
$8,600 |
CLL, other |
35% |
| Trodelvy |
$12,000 |
Breast, UC |
10% |
Venclexta's pricing model emphasizes cost-effectiveness relative to rivals, partly driving its increased utilization.
Market Trends and Future Projections
Expanding Indications
- FDA approvals for untreated CLL in combination with rituximab.
- Investigational uses in acute myeloid leukemia (AML).
Pipeline Products and Competitive Risks
- Gilead's recent acquisition of Gamida Cell announces potential targeted hematologic therapies.
- Novartis and AstraZeneca developing similar BCL-2 inhibitors.
Price Trajectory (2024–2028)
- Anticipated stabilization around current levels due to market saturation.
- Potential slight increases (2-4%) tied to inflation and manufacturing costs.
- Entry of generics remains unlikely before 2030, given patent protections.
Patent and Regulatory Environment
- Patent expiration plans extend until 2028.
- Patent litigations could delay generics, maintaining high prices.
Impact of Biosimilars and Generics
- No biosimilars exist for venetoclax.
- Generics anticipated post-2030, likely reducing prices by 60-70%.
Key Market Drivers and Constraints
Drivers:
- High efficacy in treatment-naïve patients.
- Favorable side-effect profile.
- Expanding approved indications.
Constraints:
- Competition from alternative therapies.
- Pricing pressures from payers.
- Patent challenges and legal delays.
Summary of Price Projections
| Year |
Estimated Price Changes |
Rationale |
| 2024 |
+2% |
Market stabilization; inflation. |
| 2025 |
+2% |
Cost increases and new indication coverage. |
| 2026 |
Flat or slight decrease |
Payer negotiations intensify. |
| 2027 |
Slight decline |
Patent challenges beginning. |
| 2028 |
Possible decline |
Patent expiry approaches; biosimilar entry possible. |
Key Takeaways
- NDC 51672-4146 (Venclexta) demonstrates strong growth driven by expanded indications and clinical efficacy.
- Current pricing maintains premium status at roughly $3,840/month, with limited threats from generics until after 2030.
- Market projections expect stable or modest increases in price through 2028, followed by potential significant reductions post-patent expiration.
- Competition remains robust, but Venclexta's brand positioning sustains its market dominance for the foreseeable future.
- Entry of biosimilars is unlikely before 2030, supporting sustained revenue streams and pricing.
FAQs
Q1: When is generic venetoclax expected to enter the market?
Post-2030, following patent expiration around 2028, with generic availability likely in 2030–2032.
Q2: How does Venclexta's price compare internationally?
International prices vary substantially, often lower than U.S. levels, influenced by national health policies and negotiated discounts.
Q3: What are the primary drivers for Venclexta's market share?
Clinical efficacy, expanded indications, and favorable safety profile drive adoption.
Q4: Will biosimilars significantly impact pricing?
No, as there are no biosimilars for oral small-molecule drugs like venetoclax. Generic versions post-2030 will likely be most impactful.
Q5: What regulatory or legal actions could influence future prices?
Patent litigations and regulatory delays can extend exclusivity, delaying price declines.
References
- IQVIA. (2023). Pharmaceutical Market Reports.
- U.S. Food and Drug Administration. (2022). Venclexta (venetoclax) Label.
- EvaluatePharma. (2023). World Market for Hematologic Cancer Drugs.
- CMS. (2023). Average Sales Price Data.
- Bloomberg Industry Data. (2023). Pricing Trends for Oncology Drugs.
